Medindia

X

cobas c 111 Analyzer Brings Large-Lab Performance to Smaller Labs

Friday, September 14, 2007 General News J E 4
Advertisement
INDIANAPOLIS, Sept. 13 Roche Diagnostics today announcedthe U.S. launch of the cobas c 111 system, a clinical chemistry analyzerdesigned specifically for low- to medium-volume laboratories. The compactsystem utilizes the same components and reagents as its larger, central-labCOBAS Integra siblings, enabling smaller labs to benefit from equivalentperformance and quality results.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070913/CLTH028 )

"This is the first new automated clinical analyzer designed specificallyfor the lower-volume lab segment in years," says Ken Levy, Director ofStrategic Business Development for Roche Diagnostics. "The cobas c 111 systemutilizes the same optics, reagents, cuvettes and calibrators as the largerCOBAS Integra systems, allowing labs with low to medium volumes to producecore-lab quality results quickly and conveniently. With the cobas c 111analyzer in the STAT or outpatient lab and COBAS Integra systems in thecentral lab, Integrated Health Networks are able to standardize results andquality throughout their network."

Featuring next-generation technology, the automated cobas c 111 system iseasy to use and maintain, and launches with a broad test menu. The analyzercan run up to 80 chemistry and 150 electrolyte tests per hour, and can host upto 17 onboard tests. Its continuous, random access operation allows labs torun individual tests, panels or profiles and offers STAT capability.

Launched overseas in late 2006, the cobas c 111 system is designed to bethe new gold standard for testing in satellite and low-volume labs, and bringsinnovation to that somewhat under-served niche, according to Dr. Ken Dean,Marketing Manager for Roche Diagnostics. "The cobas c 111 system completesRoche Diagnostics' clinical analyzer portfolio by bringing all of the powerand performance of a large lab analyzer down to a desktop. Essentially, thisis a COBAS Integra system engineered for smaller labs, and priced at afraction of the cost. It's designed to help healthcare professionals improve17301-37507-the quality of patient care and to help low-volume labs achieve a positivereturn on their analyzer investment."

About the cobas(R) brand

Roche Diagnostics established the cobas brand as the umbrella for productsused to complete or expand the screening, diagnostic and monitoringapplications of the professional laboratory. The cobas brand includes: serumwork area with clinical chemistry and immunochemistry, data management andpre-analytical solutions, products for coagulation analysis and urinalysis,instruments for rapid blood and cardiovascular testing and PCR-basedapplications for virology and women's health testing.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leadingresearch-focused healthcare groups in the fields of pharmaceuticals anddiagnostics. As a supplier of innovative products and services for the earlydetection, prevention, diagnosis and treatment of diseases, the Groupcontributes on a broad range of fronts to improving people's health andquality of life. Roche is a world leader in diagnostics, the leading supplierof drugs for cancer and transplantation and a market leader in virology. In2006, sales by the Pharmaceuticals Division totalled 33.3 billion Swissfrancs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs.Roche employs roughly 75,000 people in 150 countries and has R&D agreementsand strategic alliances with numerous partners, including majority ownershipinterests in Genentech and Chugai. Roche's Diagnostics Division offers auniquely broad product portfolio and supplies a wide array of innovativetesting products and services to researchers, physicians, patients, hospitalsand laboratories worldwide. For further information, please visit our websitewww.roche-diagnostics.us.COBAS, COBAS INTEGRA
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Allos Therapeutics to Present at the 2007 UBS Glob...
S
Novare Announces First Transvaginal NOTES Gallblad...